Kondaveeti, Sreenivasulu Naidu
Deep insight into the correlation between gut dysbiosis and alzheimer’s amyloidopathy - Vol.13(4), Dec - New Delhi SAGE 2022 - 305-315p.
Recent research has shown a strong correlation between gut dysbiosis and Alzheimer’s disease (AD). The purpose of this review is to investigate the relationship between gut dysbiosis, immune system activation, and the onset of AD and to examine current breakthroughs in microbiota-targeted AD therapeutics. A review of scientific literature was conducted to assess the correlation between gut dysbiosis and AD and the various factors associated. Gut dysbiosis produces an increase in harmful substances, such as bacterial amyloids, which makes the gut barrier and blood-brain barrier more permeable. This leads to the stimulation of immunological responses and an increase in cytokines such as interleukin-1β (IL-1β). As a result, gut dysbiosis accelerates the progression of AD.
The review highlights the connection between gut dysbiosis and AD and the potential for microbiota-targeted therapies in AD treatment.
PHARMACOLOGY
Deep insight into the correlation between gut dysbiosis and alzheimer’s amyloidopathy - Vol.13(4), Dec - New Delhi SAGE 2022 - 305-315p.
Recent research has shown a strong correlation between gut dysbiosis and Alzheimer’s disease (AD). The purpose of this review is to investigate the relationship between gut dysbiosis, immune system activation, and the onset of AD and to examine current breakthroughs in microbiota-targeted AD therapeutics. A review of scientific literature was conducted to assess the correlation between gut dysbiosis and AD and the various factors associated. Gut dysbiosis produces an increase in harmful substances, such as bacterial amyloids, which makes the gut barrier and blood-brain barrier more permeable. This leads to the stimulation of immunological responses and an increase in cytokines such as interleukin-1β (IL-1β). As a result, gut dysbiosis accelerates the progression of AD.
The review highlights the connection between gut dysbiosis and AD and the potential for microbiota-targeted therapies in AD treatment.
PHARMACOLOGY